Challenges in molecular analysis for individualized cancer therapy

Affiliations

Martin Clynes et al. Drug Discov Today. 2003.

. 2003 Jun 15;8(12):531.

doi: 10.1016/s1359-6446(03)02730-2.

¹ National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Ireland.

No abstract available

Similar articles

Using microarrays to predict resistance to chemotherapy in cancer patients.
Lee CH, Macgregor PF. Lee CH, et al. Pharmacogenomics. 2004 Sep;5(6):611-25. doi: 10.1517/14622416.5.6.611. Pharmacogenomics. 2004. PMID: 15335284 Review.
A gene expression database for the molecular pharmacology of cancer.
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. Scherf U, et al. Nat Genet. 2000 Mar;24(3):236-44. doi: 10.1038/73439. Nat Genet. 2000. PMID: 10700175
[Genetic alterations and chemoresistance].
Akiyama S. Akiyama S. Gan To Kagaku Ryoho. 2005 Nov;32(12):1895-901. Gan To Kagaku Ryoho. 2005. PMID: 16282723 Review. Japanese.
Tumor mRNA expression profiles predict responses to chemotherapy.
Minna JD, Girard L, Xie Y. Minna JD, et al. J Clin Oncol. 2007 Oct 1;25(28):4329-36. doi: 10.1200/JCO.2007.12.3968. J Clin Oncol. 2007. PMID: 17906194 Review. No abstract available.
Targeted therapy: overcoming drug resistance with clinical cancer genome.
Ziogas DE, Katsios CS, Tzaphlidou M, Roukos DH. Ziogas DE, et al. Expert Rev Anticancer Ther. 2012 Jul;12(7):861-4. doi: 10.1586/era.12.68. Expert Rev Anticancer Ther. 2012. PMID: 22845399 No abstract available.

MAGED4B is a Poor Prognostic Marker of Stomach Adenocarcinoma and a Potential Therapeutic Target for Stomach Adenocarcinoma Tumorigenesis.
Luo WZ, Li X, Wu XX, Shang YW, Meng DH, Chen YL, Zhang QS. Luo WZ, et al. Int J Gen Med. 2023 May 6;16:1681-1693. doi: 10.2147/IJGM.S401507. eCollection 2023. Int J Gen Med. 2023. PMID: 37181643 Free PMC article.